- Drugs
- Friday, 28 Feb 2020
Christopher Hite Joins Royalty Pharma
Chris joined Citi as Global Head of Healthcare Investment Banking in 2008 and most recently served as Vice Chairman and Global Head of Healthcare. Previously, Chris was Global Head of Healthcare Investment Banking at Lehman Brothers. He has been involved in many of the most prominent healthcare M&A transactions in recent years, including advising Celgene on its sale to Bristol-Myers Squibb for $90 billion, Tesaro on its sale to GlaxoSmithKline (GSK) for $5.1 billion, Shire on its sale to Takeda Pharmaceuticals for $82 billion, Roche on its acquisition of Spark Therapeutics for $4.3 billion and GSK on the combination of its and Pfizer's consumer health businesses. In addition, Chris has advised clients on numerous capital raising events, including Initial Public Offerings, acquisition financings, convertible bonds, leveraged financings and bond offerings.
"We are delighted to have Chris join Royalty Pharma," said Pablo Legorreta, Founder and Chief Executive Officer of Royalty Pharma. "Royalty Pharma's growth has accelerated in recent years and having someone with Chris' experience and relationships in the biopharmaceutical industry will allow us to address even larger and more complex opportunities as we embark on the next phase of our business. We are honored that Chris has chosen Royalty Pharma for the next chapter in his already highly accomplished career," Pablo Legorreta added.
"I feel extraordinarily lucky to have been at Citi for nearly 12 years," said Chris Hite. "As a result of the support of my colleagues and Citi's platform, I have had the opportunity to work on many of the most innovative transactions in the healthcare industry. I am excited to be joining an extraordinary team with a proven track record of providing creative solutions for the funding of the life sciences industry," Chris Hite added.
Chris will join Royalty Pharma in April 2020 following a transition of his responsibilities with Citi clients and transactions.
Related Industry Updates
Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts
May 26, 2020
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient
Jun 29, 2020
OTC Drug and Dietary Supplement Market Outlook, Geographical Segmentation, Industry Size & Share, Comprehensive Analysis to 2027
Sep 09, 2020
Celltrion Launches Liquid Remsima IV in Europe to Lead Infliximab Market
Mar 12, 2026
Global Recall of the Common Heartburning Drugs Over the Risk of Cancer
Jan 21, 2020
Pet Anthelmintic Drugs Market - Important Changes in Industry Dynamics
Mar 17, 2021
United Cannabis Corporation Receives Notice of Allowance for New Patent Covering Methods of Preparing and Using Cannabinoid Formulations
Dec 12, 2019